ACAD Stock Analysis

Acadia Pharmaceuticals Inc - Real-time stock metrics, market data, and comprehensive analysis

Loading...

Fetching stock data...

Acadia Pharmaceuticals Inc

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.

Market Data

Current Price

$21.84

+$0.14 (0.65%)
Market Cap

-

Total Company Value
Day Range
$21.47 - $22.03
Session Volume
1.1M
Last session total

Valuation Metrics

P/E Ratio

-

Price ÷ Earnings
EPS (Basic)

-

Earnings Per Share
Price-to-Book

-

Market Value ÷ Book Value

Financial Health

Revenue (TTM)

-

Trailing 12 Months
Net Income (TTM)

-

Profit After Tax
Gross Margin

-

Revenue Efficiency

Returns & Dividends

Dividend Yield

-

Annual Dividend ÷ Price
Annual Dividend

-

Per Share
Payout Ratio

-

Dividend ÷ EPS

Price Performance

Price Chart
All times are in Eastern Time (ET)

Recent News

No news available

Data Source: Financial data is sourced from SEC filings via Tiingo and may be delayed. Market Status: CLOSED - Showing latest available data. (Last updated: 4:51 PM)
Logos provided by Logo.dev

Contact Me

Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.